Warner-lambert Company

University of Michigan

Millennium Pharmaceuticals Limited

Michael William Wilson

David T Connor

John C Hodges

Gary Louis Bolton

Patrick Michael O'Brien

Daniel L Flynn

Paul C Unangst

Joseph Armand Picard

Catherine R Kostlan

Bruce D Roth

Drago R Sliskovic

William Chester Patt

Neil Moss

Scott D Larsen

Michael D Mullican

Mark W Creswell

Gary P Shrum

James A Shayman

Bradley Dean Tait

Joseph Scott Warmus

Richard John Booth

Daniel Fred Ortwine

Nicole Chantel Barvian

Akira Abe

Liming Shu

Richard F Keep

Helen Tsenwhei Lee

Duxin Sun

Milton L Hoefle

Karen Elaine Sexton

Amy Mae Bunker

Bernard Gaudilliere

Henri Jacobelli

Kevon Ray Shuler

Carl L Heifetz

John J G Tesmer

Jason Keith Pontrello

Kristoff Homan

Helen Waldschmidt

Stephanie Elizabeth Ault Justus

Mark Anthony Morris

Patrick Michael O'brien

John JG Tesmer

Disclosed herein are novel GRK inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein the substituents are as described. 

G protein-coupled receptor kinase inhibitors and methods for use of the same

Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.

Glucosylceramide synthase inhibitors and therapeutic methods using the same

This invention provides compounds defined by Formula I and pharmaceutically acceptable salts thereof,and pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of treating osteo- and rheumatoid arthritis.

Hetero biaryl derivatives as matrix metalloproteinase inhibitors

Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,wherein:

Pyridine matrix metalloproteinase inhibitors

A compound selected from those of formula (I):

Alkynylated quinazoline compounds

The present invention relates to fused bicyclic metalloproteinase inhibitors of the formulawherein A, B, X, Y, and Rare as defined in the specification, and to pharmaceutical compositions and methods of treating arthritis, inflammation, cancer and other disorders.

Fused bicyclic metalloproteinase inhibitors

Pyridine fused bicyclic metalloproteinase inhibitors

Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,

Pyrimidinone fused bicyclic metalloproteinase inhibitors

Benzo thiadiazine matrix metalloproteinase inhibitors

Rapid purification by polymer supported quench

Thiazolidinone compounds useful as chemokine inhibitors

Novel polymer-supported quenching reagents of Formula (I): P-L-Q, wherein P is a polymer of low chemical reactivity which is soluble or insoluble; Q is one or more quenching reagents, or an acid or base addition salts thereof, that are capable of selective covalent reaction with unwanted byproducts, or excess reagents; and L is one or more chemically robust linkers that join P and Q; are described, as well as methods for their preparation and methods for their use in the rapid purification of synthetic intermediates and products in organic synthesis, combinatorial chemistry and automated organic synthesis.

The invention concerns a series of novel bis-urea derivatives, nonpeptides, which show good binding affinity for the CCK-B receptor. The compounds, compositions containing them, methods of preparation, and utilities including anxiety, gastric acid secretion inhibition, and psychoses are included.

Agents acting at cholecystokinin receptors

Growing community of inventors

Ann Arbor, MI, United States of America

Michael William Wilson